Apimeds Pharmaceuticals US Inc. has amended the employment agreement for its Chief Executive Officer, Erik Emerson, effective November 13, 2025. Under the new terms, Emerson's annual base salary increases to $500,000. If terminated without cause, Emerson will be entitled to a severance payment equal to 24 months of base salary and benefits, along with immediate vesting of all unvested equity, contingent upon signing a release of claims. If terminated for cause or if he resigns without good reason, any unvested equity will be forfeited.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-112184), on November 18, 2025, and is solely responsible for the information contained therein.